Aclaris Therapeutics (NASDAQ:ACRS) Issues Earnings Results

Aclaris Therapeutics (NASDAQ:ACRS) released its earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04, FiscalAI reports. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.27 million.

Aclaris Therapeutics Stock Down 1.9%

Aclaris Therapeutics stock traded down $0.07 during trading on Thursday, reaching $3.61. The stock had a trading volume of 2,328,009 shares, compared to its average volume of 2,222,003. Aclaris Therapeutics has a 52-week low of $2.10 and a 52-week high of $6.60. The stock has a market cap of $504.76 million, a PE ratio of -6.22 and a beta of 0.96. The business has a 50 day moving average price of $4.72 and a 200 day moving average price of $4.53.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ACRS shares. Canaccord Genuity Group upped their price objective on Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Wedbush lowered their target price on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $11.33.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.